Savara Inc. (FRA:YB4P)

Germany flag Germany · Delayed Price · Currency is EUR
5.30
+0.74 (16.23%)
Last updated: Dec 1, 2025, 8:06 AM CET
67.72%
Market Cap1.31B
Revenue (ttm)n/a
Net Income (ttm)-98.56M
Shares Outn/a
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume3
Open5.30
Previous Close4.56
Day's Range5.30 - 5.30
52-Week Range1.66 - 5.30
Betan/a
RSI84.43
Earnings DateMar 6, 2026

About Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
Founded 2007
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YB4P
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.